Abstract
The present study was carried out to elucidate the chemopreventive potential of methanol extract of Dicranopteris linearis (MEDL) in a two-stage mouse skin carcinogenesis model due to the interrelated inflammation, oxidative stress and tumor promotion pathways. MEDL was prepared in a dose range of 30 to 300 mg/kg body weight. A total of 48 imprinting control region (ICR) female mice (6 to 8 weeks old) were randomly assorted into six groups. To induce skin tumor formation, a single topical application of 7,12-dimethylbenz[a]anthracene (DMBA) at 100 μg/100 μl was applied to the shaved dorsal region of mice, followed by repetitive administration of 1% croton oil, twice weekly for 15 weeks. Topical application of MEDL, 30 min prior to the croton oil application significantly reduced the tumor incidence to 12.5% in 300 mg/kg MEDL-treated group as compared to 87.5% in carcinogen control. The latency period of tumor formation was increased from sixth week in the carcinogen control to ninth and fifteenth weeks in 100 and 300 mg/kg MEDL-treated groups, respectively. The tumor burden of MEDL-treated groups (30, 100, and 300 mg/kg) were significantly lessen (5.67 ± 1.28, 5.00 ± 1.13, and 1.00 ± 0.13), as compared to carcinogen control (7.86 ± 2.37). The tumor volume was also significantly reduced from 9.00 ± 2.27 mm3 in carcinogen control to 3.70 ± 0.96, 2.39 ± 0.54 and 0.26 ± 0.03 mm3 in 30, 100 and 300 mg/kg MEDL-treated groups, respectively. In conclusion, the MEDL exhibited anti-carcinogenic effect in a dose-dependent manner, indicating its chemopreventive potential, which worth further study. Key words: Dicranopteris linearis, leaves, methanol extract, anti-carcinogenic effect.
Highlights
Cancer is a major public health concern worldwide and the incidence of cancer continues to increase
Among the MEDLtreated groups, both the tumor number and tumor size were reduced in Group 1, which has been treated with methanol extract of Dicranopteris linearis (MEDL) at 30 mg/kg body weight (Figure 1A), compared to Group 2, which has been treated with MEDL at 100 mg/kg body weight (Figure 1B), and almost null in Group 3, which has been treated with MEDL at 300 mg/kg body weight (Figure 1C)
The first tumor appeared simultaneously at week 6 of tumor promotion period, for Group 1, which has been treated with MEDL at 30 mg/kg body weight and Group 5
Summary
Cancer is a major public health concern worldwide and the incidence of cancer continues to increase. It is one of the leading causes of death globally. According to World Health Organization (WHO), about 7.6 million of cancer deaths were reported in 2008 and the cancer death are believed to continue rising, with an estimated 13.1 million deaths in 2030 (Siegel et al, 2011). 8,123 (44.6%) cases were diagnosed in males and 10,096 (55.4%) cases for females. The age standardized incidence rates (ASR) were 85.1/100,000 in males and 94.4/100,000 in females (Ariffin and Saleha, 2011)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
